Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Apr 20;9(4):e026030.
doi: 10.1136/bmjopen-2018-026030.

Plasma NT-proBNP levels associated with cardiac structural abnormalities in asymptomatic health examinees with preserved ejection fraction: a retrospective cross-sectional study

Eun-Hee Nah  1 , Seong Yoon Kim  2 , Seon Cho  1 , Suyoung Kim  1 , Han-Ik Cho  3
Affiliations

Plasma NT-proBNP levels associated with cardiac structural abnormalities in asymptomatic health examinees with preserved ejection fraction: a retrospective cross-sectional study

Eun-Hee Nah et al. BMJ Open. .

Abstract

Objectives: Stage B heart failure (HF) is defined as an asymptomatic abnormality of the heart structure or function. The circulating level of N-terminal pro-B-type natriuretic peptide (NT-proBNP) is elevated in symptomatic patients with left ventricular (LV) dysfunction caused by a structural or functional abnormality. This study investigated the association of the NT-proBNP level with echocardiography-detected cardiac structural or diastolic abnormalities in asymptomatic subjects with preserved LV systolic function (ejection fraction >50%).

Methods: We retrospectively studied 652 health examinees who underwent echocardiography and an NT-proBNP test at a health-promotion centre in Seoul, between January 2016 and September 2018. The left ventricular mass index (LVMI) and the left atrial dimension (LAD) were used as markers for structural abnormalities, and the mean e' velocity and mitral early flow velocity/early diastolic tissue velocity (E/e') ratio were used as markers for diastolic dysfunction. The plasma NT-proBNP level was measured using electrochemiluminescence immunoassay (DPC Immulite 2000 XPi, Siemens Healthcare Diagnostics, Tarrytown, New York, USA).

Results: Subjects with preclinical structural abnormalities were older and had a higher body mass index (BMI), higher blood pressure, lower high-density lipoprotein cholesterol level, higher NT-proBNP level, and higher E/e' (p<0.05). Multivariate regression analysis indicated that the factors associated with a higher NT-proBNP level were older age, female sex, lower BMI, higher creatinine level, higher LVMI and higher LAD (p<0.01).

Conclusion: Diastolic dysfunction is not associated with higher NT-proBNP levels, whereas preclinical cardiac structural abnormalities, as well as older age, female sex, lower BMI, and higher creatinine level, are associated with higher NT-proBNP levels.

Keywords: NT-proBNP; diastolic dysfunction; echocardiography; heart failure; preclinical structural abnormalities.

PubMed Disclaimer

Conflict of interest statement

Competing interests: None declared.

Figures

Figure 1
Figure 1
Study flow diagram. LVEF, left ventricular ejection fraction.
Figure 2
Figure 2
NT-proBNP levels according to sex and age categories. Box limits and horizontal lines within boxes represent interquartile ranges and the median, respectively. The upper and lower whiskers indicate the 97.5th and 2.5th percentiles, respectively. NT-proBNP, N-terminal pro-B-type natriuretic peptide.
Figure 3
Figure 3
NT-proBNP levels of subjects with and without structural abnormalities according to age categories. Box limits and horizontal lines within boxes represent interquartile ranges and the median, respectively. The upper and lower whiskers indicate the 97.5th and 2.5th percentiles, respectively. NT- proBNP, N-terminal pro-B-type natriuretic peptide.
Figure 4
Figure 4
Receiver operating characteristic curve and cut-off value of N-terminal pro-B-type natriuretic peptide in predicting cardiac structural abnormalities. NPV, negative predictive value; PPV, positive predictive value.
See this image and copyright information in PMC

References

    1. Ponikowski P, Voors AA, Anker SD, et al. . 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 2016;37:2129–200. 10.1093/eurheartj/ehw128 - DOI - PubMed
    1. Felker GM, Anstrom KJ, Adams KF, et al. . Effect of natriuretic peptide–guided therapy on hospitalization or cardiovascular mortality in high-risk patients with heart failure and reduced ejection fraction: a randomized clinical trial. JAMA 2017;318:713–20. 10.1001/jama.2017.10565 - DOI - PMC - PubMed
    1. Davies M, Hobbs F, Davis R, et al. . Prevalence of left-ventricular systolic dysfunction and heart failure in the Echocardiographic Heart of England Screening study: a population based study. Lancet 2001;358:439–44. 10.1016/S0140-6736(01)05620-3 - DOI - PubMed
    1. Mosterd A, Hoes AW, de Bruyne MC, et al. . Prevalence of heart failure and left ventricular dysfunction in the general population; The Rotterdam Study. Eur Heart J 1999;20:447–55. 10.1053/euhj.1998.1239 - DOI - PubMed
    1. Mureddu GF, Agabiti N, Rizzello V, et al. . Prevalence of preclinical and clinical heart failure in the elderly. A population-based study in Central Italy. Eur J Heart Fail 2012;14:718–29. 10.1093/eurjhf/hfs052 - DOI - PubMed

MeSH terms